PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Releases Record-Breaking Gross Revenue for January 2021

 

• Company reports record gross revenues of C$1,089,502 last month
• “It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” states CEO
• Record revenue comes during one of slowest e-commerce periods of year, highlighting impact the company has in the plant-based marketplace

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) saw record gross revenues last month (https://ibn.fm/qro4v). The company released its monthly numbers, noting that gross revenues for January 2021 totaled a record-breaking C$1,089,502; cost of goods sold for the month reached C$751,356.

“It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” said PlantX CEO Julia Frank. “There are many other colorful growth opportunities on the horizon, and we’re confident that our financial trajectory will reflect the remarkable and increasing value our company brings to the plant-based industry.”

PlantX Life stated that its January numbers surpassed its December 2020 gross revenues of $1,029,883, which were achieved during a highly dynamic holiday season. “This was surpassed by January 2021’s revenue, which exceeded management’s expectations given that e-commerce sales were expected to be slower following the holiday season,” the announcement noted. “This success during one of the slowest e-commerce periods of the year highlights the tremendous impact the company continues to have in the plant-based marketplace.” The announcement stated that the company’s growth reflects its commitment to meet consumer demand and continues to be driven by its innovative partnerships as well as its marketing and branding efforts.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, PlantX currently has plans to expand its product lines to include cosmetics, clothing and its own water brand.

In addition, the company uses its digital platform to build a community of like-minded consumers and to provide education. Its successful enterprise is being built and fortified through partnerships with top nutritionists, chefs and brands. For example, the company offers 20 unique pre-made meals designed by top chefs and nutritionists. These healthy meals are offered at extremely competitive prices with fast shipping and round-the-clock convenience.

The company’s commitment to customer service is the driving force behind its e-commerce platform, with innovative thinking driving its operation; the PlantX team is constantly envisioning new ways to collaborate with local restaurateurs and entrepreneurs to bring PlantX to the world. PlantX is committed to eliminating the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.

To learn more about this company, visit www.PlantX.com, www.PlantX.ca and www.Investor.PlantX.com and view the PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients

 Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost 14,000 women will die from the disease. Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women.” In a bid to change this reality, Predictive Oncology, a company that focuses on using data and artificial intelligence to develop personalized cancer therapies, has partnered with the University of Pittsburg School of Medicine, through Helomics, “to study the use of artificial intelligence (‘AI’) to improve clinical decision making for ovarian cancer patients. The collaboration entails using Helomics’ AI platform and proprietary data to analyze the genomic and drug response profiles of women with ovarian cancer to evaluate predictive values in terms of response and non-response to different treatments… Helomics’ predictive models will save time and money in the search for new targeted therapies.”

To view the full article, visit https://ibn.fm/BOt1O

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Predictive Oncology Inc. (NASDAQ: POAI) Receives ‘Buy’ Rating from Litchfield Hills Research in First Analyst Coverage Report

 

• Calling POAI undervalued, Litchfield initiates coverage of Predictive Oncology with Buy rating, $3 price target
• The drug industry is changing as tools and technology to tailor drugs emerge, regulatory bodies focus on patients’ experiences, perspectives, needs
• Litchfield report notes several POAI strengths under “Investment Thesis” section

A growing number of companies and health providers alike are paying attention to what the FDA is calling patient-focused drug development (“PFDD”), a systematic approach to help ensure that patients’ experiences, perspectives, needs and priorities are captured and meaningfully incorporated into drug development and evaluation. In that growing market, Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been given a “Buy” rating by equity research firm Litchfield Hills Research LLC, which uses a three-tiered (buy-hold-sell) rating system (https://ibn.fm/lMp50).

“If you have ever had a medical condition that had to be treated with medication that had complex dosing requirements or complex directions for taking the medication, or side effects that made you stop, the drug industry is now paying attention,” noted Litchfield’s first analyst coverage report on Predictive Oncology. “Development of drugs to treat diseases was never tailored to any one individual because the tools to do that weren’t available, so development was generally not optimized for individual patient outcomes in terms of Active Pharmaceutical Ingredients (‘API’), side effects, getting the most out of the least amount of API (bioavailability), and medication regimen complexity and adherence.

“However, that is changing, especially as tools and technology to tailor drugs emerge, and the regulatory bodies, like the FDA, are focused on patient’s experiences, perspectives and needs,” the Litchfield report continued. “As experts in what it is like to live with their condition, patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation.”

The report notes several of POAI’s strengths under its “Investment Thesis” section, including that the company is “advancing state-of-the-art patient-centric drug development systems, which is the leading edge of current drug development, as the industry tries to reduce the time needed for commercial drug development.” Other strengths include that the company operates four subsidiaries, that its commercial business provides a stable revenue stream, and that the company has a strong balance sheet, having just completed a capital raise. In addition, the report notes that POAI has an “exceptional management team. The company has assembled an experienced management team for each of its pre-commercial subsidiaries to advance them towards commercialization.”

Calling POAI undervalued, Litchfield pronounced the following: “We are initiating coverage of Predictive Oncology Inc. with a Buy rating and a $3.00 price target. Predictive Oncology Inc. (NASDAQ: POAI) is a commercial stage biotech firm tackling cancer, assisting in vaccine development and solving medical waste issues.”

Litchfield Hills Research adheres to FINRA standards for quality and objectivity. The Litchfield Hills Research Department certifies its report is compliant with FINRA research rules 2241, 3110; that Litchfield is registered with FINRA; and that the report has been reviewed by a supervisory senior analyst. Litchfield’s price target, financial models, peer comparisons and investment thesis are developed without input from management of the company, and it performs its own due diligence.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Healthtech Solutions Inc. (HLTT) Subsidiary Tech Transforms Ultrasound Images, Improves Patient Diagnosis and Care

 

• With Mediscan, the option of having scanning equipment at patient’s location is becoming increasingly viable
• Patent-pending Mediscan software converts ultrasound analog 2D grayscale image into digital 3D HD format
• Software can generate quality 3D medical images of broad variety of organs, including heart, lungs, tendons, skin and nerves

Since its introduction into the world of medicine, the ultrasound has become one of the most efficient, reliable ways to examine the human body in a noninvasive way. And now, this medical mainstay has become even more essential in providing quality care — proprietary technology from Healthtech Solutions (OTC: HLTT) subsidiary Mediscan Inc. can transform traditional 2D images from a portable ultrasound machine into invaluable 3D images to provide even more accurate internal views and, consequently, better diagnosis and health care.

“Ultrasounds give an accurate image of body parts in the least amount of time, and even allow the patient to experience real-time results,” reported a recent Mediscan blog. “In fact, [ultrasounds] can produce a high-definition image in less than ten seconds.”

That turnaround time is impressive, especially when compared to technologies such as CTs and MRIs, which can take anywhere from 24 hours to an entire week before results are available. The speed of ultrasounds becomes even more critical during emergencies, when the ability to have point-of-care ultrasound (“POCUS”) can save lives. Thanks to Mediscan, the option of having scanning equipment at a patient’s location — whether that is in an ambulance, at an assisted-living facility or even at a patient’s own home — is becoming increasingly viable.

Fundamentally, the Mediscan software converts an ultrasound analog 2D grayscale image into a digital 3D HD format. This transformation can take place in traditional ultrasound locations; the Mediscan application integrates with all popular EMR systems. In addition, because the software is designed to pair with portable ultrasound machines, it can be used in less traditional settings. The exclusive software can provide valuable insight to on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (“EMS”) personnel, and technicians in isolation wards and emergency rooms.

The process is simple. This patent-pending, cloud-based software application for ultrasound devices is easy to use wherever the internet is available. Once an image has been captured in 2D, it is converted using a cloud-based software application process. The now-3D image can be viewed on a computer monitor, pad or smartphone at the point of service, providing the convenience of point-of-care ultrasound with the image quality of CT or X-ray and the safety of expensive MRI technology. The software can generate quality 3D medical images of a broad variety of organs, including the heart, lungs, tendons, skin and nerves.

Healthtech Solutions, through its subsidiary Mediscan Inc., offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses.

For more information, visit the company’s website at www.MyMediScan.com.

NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Adobe Inc. (NASDAQ: ADBE) Featured in Simply Wall St Journal

Adobe (NASDAQ: ADBE) was featured in this week’s Simply Wall St Journal that discussed its positioning as one of the stocks that is “set to benefit from the tectonic shift to ‘all things digital.’” The piece discusses the complementary products and strong brand that Adobe has built over its nearly 40 years since inception, taking a look into how this integrated ecosystem has helped Adobe develop a competitive advantage and how its business model generates strong profitability. The piece describes the company’s business model as “enviable” with a strong advantage, particularly with its Creative Cloud offering that generates consistent revenue through subscriptions. Adobe’s software-as-a-service (“Saas”) business construct is deemed a prime example of favorable operating economics, where the software can be sold in unlimited amounts, often generating recurring income, while the cost of revenue generation is typically very low. The publication reads, “The company’s gross margins have been around 85% for the last five years and net profit margins have expanded to a very respectable 40%, from 6.1% back in 2015. As the company’s revenue has increased 21% per year since 2015 and the portion of it which is recurring revenue has increased from 67% in 2015 to over 90% in 2020, much of the revenue received can flow through to the bottom line as profit.”

For more details, visit https://ibn.fm/KMvhH

About Adobe Inc.

Adobe, an American multinational computer software company, is changing the world through digital experiences. Incorporated in Delaware and headquartered in San Jose, California, Adobe has historically focused upon the creation of multimedia and creativity software products, with a more recent foray toward digital marketing software. The company is best known for its Adobe Flash web software ecosystem, Photoshop image-editing software, Adobe Illustrator vector-graphics editor, Acrobat Reader, the Portable Document Format, and Adobe Creative Suite, as well as its successor Adobe Creative Cloud. For more information about the company, visit www.Adobe.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Online Sales Products Platform Mohawk Group Holdings Inc. (NASDAQ: MWK) Sees Outlook Rise as Result of Pandemic Trends

 

• The COVID-19 pandemic is a year old, having devastated a number of markets since its discovery and spread were first reported in China
• While many industries have suffered worldwide during the year, the distancing requirements instituted in response to the pandemic have led buyers to turn to online retail outlets for many products
• Consumer products marketer Mohawk Group Holdings has been ideally situated to take advantage of the 44 percent growth in online commerce spending during 2020 and beyond
• Mohawk’s stock took an initial beating with the outbreak of the pandemic, but has since rebounded and rose more than 400 percent during the past three months alone
• The company’s holdings saw sales grow from $88.8 million to $144.2 million during the first nine months of 2020

Consumer products platform Mohawk Group Holdings (NASDAQ: MWK)  is riding a wave of optimism as an online retail marketer benefitting from the spike in remote access purchasing during the year-old COVID-19 pandemic.

Mohawk principally leverages its proprietary technology as a third-party seller on Amazon, and grew sales revenue from $88.8 million to $144.2 million during the first nine months of 2020 reported in its most recent quarterly filing (https://ibn.fm/TyCKQ).

An outside market opinion writer published this month in media outlet The Motley Fool noted that the company’s shares took a huge dive when the pandemic provoked strict commerce-limiting measures throughout the United States last year, but has also sharply rebounded.

“Yes, the stock is up over 400% in the past three months, but it is still early innings for this tech-enabled CPG (consumer packaged goods) conglomerate, so don’t fool yourself into thinking you’ve missed the boat with this business,” the opinion writer, Brett Schafer, states (https://ibn.fm/yV8Jc).

Schafer cited a Digital Commerce 360 report stating that e-commerce has experienced tremendous growth during the past year, with online shopping forming more than 20 percent of retail spending in the United States during 2020. The $861 billion spent online was a 44 percent increase over the previous year.

Amazon captured nearly a third of the online market share, with sales growth of 54 percent during the final quarter of the year. Mohawk’s position as a third-party Amazon seller allows it to ride the commerce giant’s coattails.

The company’s Artificial Intelligence Mohawk E-commerce Engine (“AIMEE”) helps it identify market opportunities then design, develop and launch products from its stable of 12 brands in categories including kitchenware and home appliances, environmental appliances, beauty products and consumer electronics.

Mohawk also sells its AIMEE software to other online sellers, granting the company revenue with high margins and a huge market opportunity. The company has offices in the United States, Canada, China and the Philippines and takes advantage of its global footprint to move its products around the clock.

The platform’s Fulfillment Engine helps to guide inventory location, cost optimization and use of third-party networks to cut shipping times.

When Mohawk announced the acquisition of online essential oils seller Healing Solutions, LLC in early February, the company reported it expects the acquisition to help boost its net revenues for 2021 to a range between $340 million to $370 million, with net income for the year estimated to reach between $1 million and $5 million primarily in response to quarterly interest expense, net and stock-based compensation expense.

Mohawk forecasts its adjusted EBITDA will be between $28 million and $32 million.

For more information, visit the company’s website at www.Mohawkgp.com.

NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Better Cancer Outcomes Possible with Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology

 

• Imagin Medical Inc.’s patented i/Blue System revolutionizes the way surgeons are able to visualize the bladder and identify cancers during surgery
• The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies
• Bladder cystoscopies first target – multiple other endoscopic procedures planned

Science and technology have continued to make striking advancements in cancer therapeutics and treatment protocols, improving upon on past successes and creating better outcomes for cancer patients. A prime example is an exciting new development in visualizing cancer during minimally invasive surgeries. Surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF), is establishing a new paradigm in a doctor’s ability to “see” and surgically treat cancers. With bladder cancer as its first target, Imagin Medical’s initial product is the i/Blue Imaging™ System. The company’s patented, ultrasensitive imaging technology is based on advanced optics and light sensors and employs ultrasensitive imaging technology. Identifying potential early-stage tumors can be difficult because of the inability to distinguish between healthy tissue and tumors when viewed through a scope only using conventional white light.

Cystoscopy is the conventional diagnostic procedure for visualizing bladder cancer during surgery. It allows the doctor to see inside the body with a thin, lighted, flexible tube called a cystoscope which uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Like a roadmap with street signs, white light images show the full landscape of the bladder but do not effectively highlight cancer. A promising new modality, blue light cystoscopy, uses blue-filtered white light to detect flat tumors and cancerous cells not seen with white light that may be left behind during surgical removal of the tumor. However, surgeons can’t operate using blue light images. The blue images aren’t in real time, orientation in the bladder is easily lost and the surgeon must manually switch from white to blue cystoscopy and back again.

Both white and blue light cystoscopies have effective uses and serious limitations in seeing the landscape of the bladder and identifying all the cancerous cells during surgery. Missing any cancerous cells poses serious concerns because they will continue to grow and spread to other parts of the bladder, a fact reflected by the recurrence rate of fifty per cent.

The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies. By combining the white and blue light with an FDA-approved imaging agent, the i/Blue System displays side-by-side images in real-time, without the necessity to switch back and forth between the two images. Unlike any other modalities on the market today, Imagin Medical’s i/Blue Imaging System can attach to almost any endoscope model currently in use which creates a plug and play state-of-the-art system adaptable to virtually any clinical setting.

Imagin Medical is advancing the i/Blue Imaging System toward commercialization. The FDA approval process is underway, and the company’s intellectual property is well-protected. Perhaps even more significant, Imagin intends to build on the i/Blue technology which will facilitate entry into multiple other endoscopic procedures. Imagin Medical is improving on past technologies and creating better outcomes for patients while even at a reduced cost.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php